Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Artios Pharma Ltd
Multitude Therapeutics Inc.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Astellas Pharma Inc
Eli Lilly and Company
Qilu Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
AstraZeneca
Akeso
Akeso
Eli Lilly and Company
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Seagen Inc.
CEBIOTEX
Mirati Therapeutics Inc.
OncoSil Medical Limited
AstraZeneca
Novartis
Luye Pharma Group Ltd.
FBD Biologics Limited
Novartis
SN BioScience
J-Pharma Co., Ltd.
Onconic Therapeutics Inc.
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
MOMA Therapeutics
Daiichi Sankyo
IMGT Co., Ltd.
CStone Pharmaceuticals
TransThera Sciences (Nanjing), Inc.
Taiho Oncology, Inc.
EMD Serono
AbbVie
Revolution Medicines, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Akeso
Bristol-Myers Squibb
Bristol-Myers Squibb
Shanghai JMT-Bio Inc.
Pfizer
Toray Industries, Inc
Actuate Therapeutics Inc.
PharmaMar
Gilead Sciences